PCYN (Procyon) Debt-to-Asset : 0.10 (As of Jun. 2024)

View and export this data going back to . Start your Free Trial

What is Procyon Debt-to-Asset?

Procyon's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.18 Mil. Procyon's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.14 Mil. Procyon's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was $3.20 Mil. Procyon's debt to asset for the quarter that ended in Jun. 2024 was 0.10.

Procyon Debt-to-Asset Historical Data

The historical data trend for Procyon's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Procyon Debt-to-Asset Chart

Procyon Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Debt-to-Asset

Get a 7-Day Free Trial

0.07

0.19

0.17

0.14

0.10

Procyon Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Debt-to-Asset	Get a 7-Day Free Trial															0.14	0.13	0.13	0.11	0.10

Competitive Comparison of Procyon's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Procyon's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Procyon's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Procyon's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Procyon's Debt-to-Asset falls into.

Procyon Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Procyon's Debt-to-Asset for the fiscal year that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.181	+	0.139)	/	3.204
	=	0.10

Procyon's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.181	+	0.139)	/	3.204
	=	0.10

Procyon (OTCPK:PCYN) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Procyon Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Procyon's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Procyon Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Procyon Corp (OTCPK:PCYN) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

164 Douglas Road, Oldsmar, FL, USA, 34677

Website

https://www.procyoncorp.com

Procyon Corp is a United-based company, through its subsidiary, it is engaged in developing and marketing proprietary medical products used to treat pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems. Its wound care products are sold through distributors to institutional customers such as hospitals, wound care clinics, skilled nursing facilities, home health agencies, and physicians and other healthcare practitioners. The firm's product lines are AMERX, AMERIGEL, and HELIX3 Bioactive Collagen. The skin and wound care products are marketed under the trademark AMERIGEL which contains the proprietary ingredient OAKIN which promotes wound healing and healthy skin. The corporation markets its products in the United States.

Executives

Foundation Speer	10 percent owner	2535 SUCCESS DRIVE, ODESSA FL 33556
Suggs Fred Wilson Jr	director	60 FOREST LANE, GREENVILLE SC 29605
Steven Mccomas	director	800 LASTAHOUSE DRIVE, VIDALIA GA 30474
Monica Mccullough	director	1095 55TH TERR SO, SAINT PETERSBURG FL 33705
Joseph Raymond Treshler	director	PO BOX 5719, CLEARWATER FL 33758
George Otis Borak	officer: Vice President	3300 COVE CAY DR, UNIT 7D, CLEARWATER FL 33760
Lynnda L Speer	10 percent owner	2535 SUCCESS DRIVE, ODESSA FL 33556
Richard M. Speer	10 percent owner	104 WOODMONT BOULEVARD, SUITE 415, NASHVILLE TN 37205
Speer Roy M Foundation	10 percent owner	2535 SUCCESS DRIVE, ODESSA FL 33556
Paul Edward Kudelko	director	28 WINSTON DR, BELLEAIR FL 33756
Justice Wolfe Anderson	director, officer: VP-Sales and Marketing	1300 S HIGHLAND AVE, CLEARWATER FL 33756
Regina Wolfe Anderson	director	1300 S HIGHLAND AVE, CLEARWATER FL 33756
Jeffrey S Slowgrove	director	C/O INFORMATION MANAGEMENT RESOURCES INC, 26750 US HIGHWAY N #500, CLEARWATER FL 34621
John C Anderson Trust	10 percent owner	440 S GULFVIEW BLVD, APT 1702N, CLEARWATER FL 33767
Michael Timothy Foley	director	2284 KINGS POINT DRIVE, LARGO FL 33774

Procyon Headlines

No Headlines